Kelonia Therapeutics Presents Updated First-in-Human Data from Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Kelonia reported updated Phase 1 data for KLN-1010 showing a 100% overall response rate and MRD-negative bone marrow responses in all evaluable patients, with the earliest dosed patients remaining MRD-negative beyond 9-10 months. Safety remained favorable, with mostly Grade 1-2 CRS in 16 of 18 patients, only one Grade 3 ICANS event, and no delayed neurotoxicity or infusion reactions after dexamethasone premedication. The data support continued outpatient dosing and reinforce the case for the company's in vivo CAR-T platform ahead of Eli Lilly's pending acquisition.

Analysis

The signal here is less about today’s efficacy headline and more about what it implies for the adoption curve of in vivo cell therapy. If the outpatient, no-lymphodepletion workflow holds, the addressable pool expands from tertiary-center CAR-T candidates to a much broader myeloma population that is currently blocked by logistics, bed availability, and referral friction. That creates a meaningful strategic threat to incumbents in ex vivo BCMA CAR-T, because the economic moat shifts from manufacturing scale to delivery simplicity and time-to-treatment.

For Lilly, the optionality is asymmetric: the announced acquisition looks increasingly like a platform tuck-in rather than a single-asset bet, and positive durability data can justify a higher internal probability of success across adjacent in vivo hematology programs. The second-order effect is on trial design and capital allocation across the space—competitors may now need to prove not just response depth but operational superiority versus an outpatient standard, which is a higher bar for autologous CAR-T and a tough one for emerging allogeneic approaches that still rely on complex infrastructure.

The main risk is follow-up duration. The market will likely extrapolate a 100% ORR too aggressively from a small cohort, but the real inflection is whether responses remain durable past 12 months while late cytopenias, infections, or neurotoxicity stay muted. Any signal of convergence with classic CAR-T toxicity, vector-related immunogenicity, or dose-limiting manufacturing variability would compress the current narrative quickly; conversely, a clean dataset into the next 2-3 updates should support a re-rating of the platform value rather than the single-asset value.

Key Decisions for Investors

• Maintain a tactical long bias in LLY for 1-3 months into the next data cadence and transaction close; upside is that the market may start assigning platform optionality, while downside is limited by Lilly’s diversified earnings base.
• Use any post-release strength in ex vivo BCMA CAR-T names as a shorting opportunity against LLY over 4-8 weeks; the risk/reward favors a relative-value pair because this dataset increases the probability of share loss at the margin for complex center-based therapy.
• If liquid, buy medium-dated LLY upside via call spreads into the next clinical update window; the catalyst path is cleaner than common-equity beta and limits downside if follow-up data disappoints.
• Avoid outright long exposure to early-stage in vivo CAR-T private comps until durability beyond 9-12 months is visible; the current data de-risks response, not commercial scale, and that gap is where most of the valuation risk sits.
• Set a review trigger on the next 10-15 patient additions: if outpatient dosing remains intact with no late toxicity uptick, increase conviction on the platform thesis; if not, fade the headline and rotate back to proven ex vivo leaders.